Upstate Capital is proud to honor leaders whose work pushes boundaries, accelerates breakthroughs and brings meaningful change to communities across New York and beyond. This year, we are excited to recognize Tal Gilat, Chief Executive Officer of Neurogenesis Ltd., as the winner of Upstate Capital’s Impact Investment of the Year Award. This award highlights individuals and teams whose vision and execution create measurable, lasting value for both investors and consumers.
Advancing Regenerative Medicine for Neurodegenerative Diseases
Tal leads Neurogenesis Ltd., a clinical-stage biotechnology company committed to developing regenerative cell therapies for some of the most challenging neurodegenerative diseases. The company’s groundbreaking work aims to address conditions that have long lacked effective treatment options. Their goal is to offer new hope to patients and families navigating these diagnoses.
With more than 17 years of experience guiding both public and private companies, Tal brings a strong combination of scientific understanding, business strategy and operational excellence to the field. His leadership has helped position Neurogenesis as an emerging force in the biotech landscape and as an influential contributor to the broader innovation economy.
A Career Built on Vision and Growth
Tal’s career spans Tel Aviv, New York and Silicon Valley, where he has consistently led teams through pivotal stages of growth. His experience across multiple sectors, including software and biotechnology, gives him a unique perspective on bringing transformative technologies to market.
Tal holds an MBA from Columbia Business School and a BA in Economics and Business Administration from the Hebrew University of Jerusalem. His achievements have been recognized by respected institutions and patient advocacy groups that share his commitment to improving patient outcomes and expanding access to new therapies.
Leadership with Purpose
Tal’s work exemplifies the values behind the Impact Investment of the Year Award. His strategic approach, ability to guide high-performing teams and dedication to developing therapies that can change lives reflect the spirit of innovation that drives progress in our region.
The technologies and treatments emerging from Neurogenesis represent the kind of forward-looking investment that strengthens the life sciences ecosystem and fuels long-term growth. Tal’s leadership has helped accelerate that journey, contributing to advancements that hold significant promise for patients and communities.
Celebrating Meaningful Impact
Tal’s achievements highlight the powerful results that can emerge when talent, vision and collaboration come together. We are honored to recognize his contributions and to celebrate the impact Neurogenesis continues to make in the biotechnology sector.
Congratulations to Tal Gilat on receiving Upstate Capital’s Impact Investment of the Year Award!